Data from: Large scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine

  • Gerrit L J Onderwater (Contributor)
  • Lannie Ligthart (Contributor)
  • Mariska Bot (Contributor)
  • Ayse Demirkan (Contributor)
  • Jingyuan Fu (Contributor)
  • Carla J H van der Kallen (Contributor)
  • Lisanne S Vijfhuizen (Contributor)
  • René Pool (Contributor)
  • Jun Liu (Contributor)
  • Floris H M Vanmolkot (Contributor)
  • Marian Beekman (Contributor)
  • Hoyan Wen (Contributor)
  • Najaf Amin (Contributor)
  • Carisha S Thesing (Contributor)
  • Judith A Pijpers (Contributor)
  • Dennis A Kies (Contributor)
  • Ronald Zielman (Contributor)
  • Irene de Boer (Contributor)
  • Marleen M. J. Van Greevenbroek (Contributor)
  • Ilja C W Arts (Contributor)
  • Yuri Milaneschi (Contributor)
  • Miranda T Schram (Contributor)
  • Pieter C Dagnelie (Contributor)
  • Lude Franke (Contributor)
  • M. Arfan Ikram (Contributor)
  • Michel D Ferrari (Contributor)
  • Jelle J Goeman (Contributor)
  • P. Eline Slagboom (Contributor)
  • Cisca Wijmenga (Contributor)
  • Coen D.A. Stehouwer (Contributor)
  • DI Boomsma (Contributor)
  • Cornelia M van Duijn (Contributor)
  • Brenda W. Penninx (Contributor)
  • Peter a.C ’t Hoen (Contributor)
  • Gisela M Terwindt (Contributor)
  • Arn M J M van den Maagdenberg (Contributor)

Dataset

Description

Objective: To identify a plasma metabolomic biomarker signature for migraine. Methods: Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test analysis was performed to identify sets of related metabolites associated with migraine. The Holm procedure was applied to control the family-wise error rate at 5% in single-metabolite and global test analyses. Results: Decreases in the level of apolipoprotein A1 (β −0.10; 95% confidence interval [CI] −0.16, −0.05; adjusted p = 0.029) and free cholesterol to total lipid ratio present in small high-density lipoprotein subspecies (HDL) (β −0.10; 95% CI −0.15, −0.05; adjusted p = 0.029) were associated with migraine status. In addition, only in male participants, a decreased level of omega-3 fatty acids (β −0.24; 95% CI −0.36, −0.12; adjusted p = 0.033) was associated with migraine. Global test analysis further supported that HDL traits (but not other lipoproteins) were associated with migraine status. Conclusions: Metabolic profiling of plasma yielded alterations in HDL metabolism in migraine patients and decreased omega-3 fatty acids only in male migraineurs.,Methods_e-1_Cohort_backgroundMethods e-1 Cohort background, migraine assessment method, and sampling procedure.Figure_e-1_Influence_of_HeritabilityFigure e-1: Influence of heritability on metabolite estimates and log p-values in ERF and NTR.Figure_e-2_Ratio_stratification_plots_migraine_smokingFigure e-2: ApoA1 and S-HDL-FC ratio stratification plots for migraine and smoking in NESDA and LUMINA.Figure_e-3_Ratio_stratification_plots_migraine_lipid_lowering_medicationFigure e-3: ApoA1 and S-HDL-FC ratio stratification plots for migraine and lipid lowering medication usage in NESDA and LUMINA.Figure_e-4_Ratio_stratification_plots_migraine_fastingFigure e-4: ApoA1 and S-HDL-FC ratio stratification plots for migraine and fasting in NESDA and LUMINA.Figure_e-5_Ratio_stratification_plots_migraine_depressionFigure e-5: ApoA1 and S-HDL-FC ratio stratification plots for migraine and depression in NESDA and LUMINA.Figure_e-6_Ratio_stratification_plots_migraine_body_mass_indexFigure e-6: ApoA1 and S-HDL-FC ratio stratification plots for migraine and body mass index in NESDA and LUMINA.Figure_e-7_Metabolite_correlation_between_measurements_and_over_timeFigure e-7: Metabolite correlations between measurements and over time for apoA1 and the S-HDL-FC ratio.Figure_e-8_HDL_feature_plots_for_all_individual_cohortsFigure e-8: HDL feature plots for all individual cohorts.Table_e-1_Included_metabolites_in_pathwaysTable e-1: Included metabolites in (sub-)pathwaysTable_e-2_Included_metabolite_ratiosTable e-2: Included metabolite ratio’sTable_e-3_Results_from_logistic_regression_sex_age_migraineTable e-3: Results from logistic regression with metabolite concentrations, sex, and age as independent variables and migraine status as dependent variable.Table_e-4_Meta_analysis_results_of_the_logistic_regressionTable e-4: Meta-analysis results of the logistic regressions with sex, age, and metabolite concentrations as independent variables and migraine status as dependent variable.Table_e-5_Results_logistic_regression_LLM_BMI_sex_age_migraineTable e-5: Results logistic regression with metabolite concentrations, lipid lowering medication usage, body mass index, sex, and age as independent variables and migraine status as dependent variable.,
Date made available1 Jan 2019
PublisherUnknown Publisher

Cite this